Naslov
Molecular Mechanisms of Resistance to Immune Checkpoint Inhibitors in Melanoma Treatment: An Update

Autori
Vukadin, Sonja ; Khaznadar, Faraf ; Kizivat, Tomislav ; Vcev, Aleksandar ; Smolic, Martina

Izvornik
Biomedicines (2227-9059) 9(7):835 (2021), 9(7):835; 1-34

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, pregledni rad, znanstveni

Ključne riječi
drug resistance ; immune check-point inhibitors ; immunotherapy ; ipilimumab ; melanoma ; nivolumab ; pembrolizumab.

Sažetak
Over the past decade, immune checkpoint inhibitors (ICI) have revolutionized the treatment of advanced melanoma and ensured significant improvement in overall survival versus chemotherapy. ICI or targeted therapy are now the first line treatment in advanced melanoma, depending on the tumor v-raf murine sarcoma viral oncogene homolog B1 (BRAF) mutational status. While these new approaches have changed the outcomes for many patients, a significant proportion of them still experience lack of response, known as primary resistance. Mechanisms of primary drug resistance are not fully elucidated. However, many alterations have been found in ICI-resistant melanomas and possibly contribute to that outcome. Furthermore, some tumors which initially responded to ICI treatment ultimately developed mechanisms of acquired resistance and subsequent tumor progression. In this review, we give an overview of tumor primary and acquired resistance mechanisms to ICI and discuss future perspectives with regard to new molecular targets and combinatorial therapies.

Izvorni jezik
Engleski

POVEZANOST RADA